Natco Pharma issues clarification on CDSCO approval, rules out material impact; stock gains 11% this weekNatco Pharma issues clarification on CDSCO approval, rules out material impact; stock gains 11% this week

Introduction

Leading Indian pharmaceutical firm received regulatory approval for Semaglutide. The company plans to launch the product in March 2026 with multiple marketing partners, including Eris Lifesciences Ltd.

Also Read: Sigma Advanced Systems locks 5% upper circuit after ₹100 Cr defence order win

Share price movement of Natco Pharma

On February 25, 2026, Natco Pharma Ltd opened at ₹949.95, up 0.59% from its previous close of ₹944.45. The stock reached a high of ₹990.45 (4.82%) and a low of ₹942.85. By 12:23 PM, it traded at ₹979.25, a 3.68% increase, with a market cap of ₹17,539.33 crore.

Natco Pharma Semaglutide Launch Update

Natco Pharma Limited has clarified reports about its Semaglutide product in India. The company received approval from CDSCO on February 14, 2026, for marketing the product in India.

Natco Pharma is working with multiple marketing partners to launch Semaglutide in March 2026. Partnership with Eris Lifesciences Ltd is in the ordinary course of business and has no operational impact.

The company stated there is no undisclosed information affecting trading. The article has no material financial impact, and Natco Pharma continues regular disclosures as per SEBI LODR Regulations.

Stock performance of Natco Pharma for period of 1 week, 6 months, and 1 year

Natco Pharma Ltd gained 10.90% over the past week, rose 16.61% in the past 6 months, and increased 18.0% over the past 1 year.

Also Read: Pace Digitek soars 4% after arm bags ₹1,587 million Reliance Industries order

Shareholding pattern of Natco Pharma

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	49.50%	49.50%	49.60%
FII	15.20%	14%	15.50%
DII	5.40%	5.90%	5.80%
Public	30.00%	30.60%	29.10%

About Natco Pharma

Natco Pharma Ltd (NSE: NATCOPHARM) is a research-driven pharmaceutical company developing, manufacturing, and marketing complex products across FDF, APIs, and contract manufacturing business segments.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs